356 related articles for article (PubMed ID: 27104980)
21. MAP kinase activation is essential for oncogenic transformation of NIH3T3 cells by Mos.
Okazaki K; Sagata N
Oncogene; 1995 Mar; 10(6):1149-57. PubMed ID: 7700641
[TBL] [Abstract][Full Text] [Related]
22. Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system.
Papin C; Denouel A; Calothy G; Eychène A
Oncogene; 1996 May; 12(10):2213-21. PubMed ID: 8668348
[TBL] [Abstract][Full Text] [Related]
23. Cysteine-rich region of Raf-1 interacts with activator domain of post-translationally modified Ha-Ras.
Hu CD; Kariya K; Tamada M; Akasaka K; Shirouzu M; Yokoyama S; Kataoka T
J Biol Chem; 1995 Dec; 270(51):30274-7. PubMed ID: 8530446
[TBL] [Abstract][Full Text] [Related]
24. Cell cycle-dependent phosphorylation of C/EBPbeta mediates oncogenic cooperativity between C/EBPbeta and H-RasV12.
Shuman JD; Sebastian T; Kaldis P; Copeland TD; Zhu S; Smart RC; Johnson PF
Mol Cell Biol; 2004 Sep; 24(17):7380-91. PubMed ID: 15314150
[TBL] [Abstract][Full Text] [Related]
25. How Ras works: structure of a Rap-Raf complex.
Sprang SR
Structure; 1995 Jul; 3(7):641-3. PubMed ID: 8591040
[TBL] [Abstract][Full Text] [Related]
26. The RAS-Binding Domain of Human BRAF Protein Serine/Threonine Kinase Exhibits Allosteric Conformational Changes upon Binding HRAS.
Aramini JM; Vorobiev SM; Tuberty LM; Janjua H; Campbell ET; Seetharaman J; Su M; Huang YJ; Acton TB; Xiao R; Tong L; Montelione GT
Structure; 2015 Aug; 23(8):1382-1393. PubMed ID: 26165597
[TBL] [Abstract][Full Text] [Related]
27. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1.
Lucas L; Penalva V; Ramírez de Molina A; Del Peso L; Lacal JC
Int J Oncol; 2002 Sep; 21(3):477-85. PubMed ID: 12168089
[TBL] [Abstract][Full Text] [Related]
28. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
29. The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site.
Mott HR; Carpenter JW; Zhong S; Ghosh S; Bell RM; Campbell SL
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8312-7. PubMed ID: 8710867
[TBL] [Abstract][Full Text] [Related]
30. Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation.
Urano T; Emkey R; Feig LA
EMBO J; 1996 Feb; 15(4):810-6. PubMed ID: 8631302
[TBL] [Abstract][Full Text] [Related]
31. Activation of the Raf/MAP kinase cascade by the Ras-related protein TC21 is required for the TC21-mediated transformation of NIH 3T3 cells.
Rosário M; Paterson HF; Marshall CJ
EMBO J; 1999 Mar; 18(5):1270-9. PubMed ID: 10064593
[TBL] [Abstract][Full Text] [Related]
32. Molecular dynamics simulations of the Ras:Raf and Rap:Raf complexes.
Zeng J; Treutlein HR; Simonson T
Proteins; 1999 Apr; 35(1):89-100. PubMed ID: 10090289
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M
Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399
[TBL] [Abstract][Full Text] [Related]
34. Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Ikenoue T; Kanai F; Hikiba Y; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Asaoka Y; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
Mol Carcinog; 2005 May; 43(1):59-63. PubMed ID: 15791648
[TBL] [Abstract][Full Text] [Related]
35. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.
Yan C; Saleh N; Yang J; Nebhan CA; Vilgelm AE; Reddy EP; Roland JT; Johnson DB; Chen SC; Shattuck-Brandt RL; Ayers GD; Richmond A
Mol Cancer; 2021 Jun; 20(1):85. PubMed ID: 34092233
[TBL] [Abstract][Full Text] [Related]
36. N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence.
Wang Z; Liu Y; Takahashi M; Van Hook K; Kampa-Schittenhelm KM; Sheppard BC; Sears RC; Stork PJ; Lopez CD
Proc Natl Acad Sci U S A; 2013 Jan; 110(1):312-7. PubMed ID: 23248303
[TBL] [Abstract][Full Text] [Related]
37. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
[TBL] [Abstract][Full Text] [Related]
38. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling.
Villalonga P; López-Alcalá C; Bosch M; Chiloeches A; Rocamora N; Gil J; Marais R; Marshall CJ; Bachs O; Agell N
Mol Cell Biol; 2001 Nov; 21(21):7345-54. PubMed ID: 11585916
[TBL] [Abstract][Full Text] [Related]
39. Quantitative structure-activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo.
Block C; Janknecht R; Herrmann C; Nassar N; Wittinghofer A
Nat Struct Biol; 1996 Mar; 3(3):244-51. PubMed ID: 8605626
[TBL] [Abstract][Full Text] [Related]
40. Interactions between Ras proteins and their effectors.
McCormick F; Wittinghofer A
Curr Opin Biotechnol; 1996 Aug; 7(4):449-56. PubMed ID: 8768906
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
